Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

Abstract Type 2 diabetes (T2D), which has currently become a global pandemic, is a
metabolic disease largely characterised by impaired insulin secretion and action. Significant …

Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects a large part of
population and according to the World Health Organization (WHO) the number of adults …

Insulin resistance in muscle and liver and-cell failure represent the core pathophysiologic
defects in type 2 diabetes. It now is recognized that the-cell failure occurs much earlier and …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …

The incretin system is an essential metabolic axis that regulates postprandial metabolism.
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic …

Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose
concentrations, lipid metabolism, gut motility, appetite and body weight, and immune …

Dipeptidyl peptidase 4 inhibitors (DPP4i) have been available for treating type 2 diabetes
mellitus since 2006. Although they are a diverse group, DPP4i are all small, orally available …

Objective A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to
determine whether the metabolic action of GIP adds to the established clinical benefits of …